证券日报网讯1月6日，贝达药业（300558）在互动平台回答投资者提问时表示，公司一贯遵循法律法规 及交易所规则，对于应当披露事项的进展情况及时履行披露义务。根据实际业务开展的需要，公司推进 BPI-572270项目的临床申报工作，完成的工作节点均不属于公司法定披露的时点。目前，项目的临床申 请正在审核当中，如有重大进展，公司会及时公告披露。 ...

证券日报网讯1月6日，贝达药业（300558）在互动平台回答投资者提问时表示，杭州景曜生物科技有限 责任公司自2025年10月成立后尚未进行实际业务的开展，公司受让股权除了承担该公司的注册资本出资 责任外，未支付其他费用。 ...

证券日报网讯1月6日，贝达药业（300558）在互动平台回答投资者提问时表示，公司已按工作业务的相 关进展预约2026年4月23日为2025年年度报告披露日。目前公司经营正常，2025年经营业绩相关信息请 以公司公开披露为准。 ...

2025年12月31日，海南省人民政府办公厅发布《海南省加快推进中医药产业高质量发展三年行动方案 （2026-2028年）》，目标是到2028年底，培育中药材良种良苗繁育园及"定制药园"10个以上，中药材 种植养殖总面积100万亩以上，建成产地分拣加工中心和市县级贮藏中心20个以上，新增医疗机构院内 制剂备案号或批准文号10个以上，打造6条以上特色中医药康养旅游精品路线，力争中医药全口径产值 增长15%。《方案》总计20项重点任务，包括：攻坚种源，补强道地药材繁育链；规范生产，补齐标准 化种植养殖链；升级加工，补充高效产地加工链；畅通渠道，补好产地流通供应链；加强饮片精制，促 进优质优价；加强制剂创新，实现技术突破等。 药械审批 兴齐眼药：硫酸阿托品滴眼液取得注册证 1月4日，兴齐眼药(300573.SZ)公告称，公司收到国家药品监督管理局核准签发的硫酸阿托品滴眼液 《药品补充申请批准通知书》。该药品适用于延缓球镜度数为-1.00D至-4.00D（散光≤1.50D、屈光参差 ≤1.50D）的6至12岁儿童的近视进展。公司在已上市硫酸阿托品滴眼液基础上增加两个产品规格，分别 为0.02%（0.4ml：0.08m ...

人民财讯1月4日电，据国药控股消息，近日，"国药控股&贝达药业战略合作签约仪式暨项目启动会"在 贝达总部举行。面向未来，国药控股与贝达药业将持续深化合作、智联共进，携手打造协同高效的医药 供应链新生态。 转自：证券时报 ...

国药控股副总裁胡立刚表示，国药控股非常高兴能与贝达药业达成战略合作。国药控股将持续整合内部 资源、优化服务模式，致力于为以贝达药业为代表的创新型企业提供更好的支持。他希望能以此次战略 合作为起点，推动双方合作迈入新阶段。 贝达药业董事长丁列明表示，贝达的发展离不开国药控股的大力支持。作为全国医药流通企业，国药控 股在贝达商业化进程中发挥了重要作用。随着双方合作的不断深化，不仅能进一步发挥国药控股的优势 资源，也助力贝达创新生态圈产出更多协同创新成果，更好地惠及患者。 近日，"国药控股&贝达药业战略合作签约仪式暨项目启动会"在贝达总部举行。 此次国药控股与贝达药业深度携手，是"创新药企"与"供应链巨头"优势互补、强强联合的典范。面向未 来，国药控股与贝达药业将持续深化合作、智联共进，携手打造协同高效的医药供应链新生态。 ...

Core Insights - The domestic pharmaceutical industry faced unprecedented challenges in 2025 due to policy adjustments, capital withdrawal, and intense competition, leading to a brutal industry reshuffle [2] - The shift in industry dynamics emphasizes clinical value as the core focus, with capital returning to rationality and competition shifting towards hard power [2] Group 1: Company Failures - *ST Changyao faced multiple crises, including a failed restructuring and financial fraud, resulting in a net asset of -643 million yuan and facing dual delisting risks [3] - Simi Biological, an early player in the mRNA field, entered bankruptcy liquidation due to a broken funding chain after raising over 1.3 billion yuan from 2020 to 2023 [5] - Green Valley Pharmaceutical's core product, "Jiuyi Yi," faced production halts due to expired registration and financial difficulties, leading to operational paralysis [6] - *ST Longjin was delisted due to reliance on a single product, with sales dropping significantly after price reductions and failed diversification attempts [7] - Shanghai Jinzhongnuomei, once a rising star, faced bankruptcy liquidation due to funding issues and high R&D costs [8] - Lizhu Group exited the PD-1 market after incurring significant losses, highlighting the challenges of entering saturated markets [9] - Ruike Biological's founder lost control of the company despite nearing commercialization of a core product, reflecting the struggles of innovation-driven firms [10] - Betta Pharmaceuticals faced a trust crisis due to overdue milestone payments, exposing cash flow issues in the innovative drug sector [11] - Keyuan Pharmaceutical's 3.58 billion yuan acquisition plan fell through, missing a critical transformation opportunity amid market changes [13] - Jikai Gene's founder faced legal issues due to an inability to repay 227 million yuan in debt, illustrating the pressures of capital constraints on companies [14]

Core Viewpoint - The A-share pharmaceutical sector in 2025 exhibits structural differentiation, with innovative drugs and CXO sectors thriving due to overseas demand and business development, while traditional Chinese medicine, medical devices, and pharmaceutical commerce face performance pressures [3][20]. Summary by Category Overall Market Performance - The A-share pharmaceutical and biotechnology sector saw an overall increase of 25.64% from January 1 to December 30, 2025, despite a slight decline in revenue and a stabilization in profits, with total revenue of 18,544.52 billion yuan, down 1.42% year-on-year, and net profit of 1,407.32 billion yuan, down 1.65% year-on-year [4][21]. Innovative Drug Sector - The innovative drug sector was a standout performer in 2025, with the chemical pharmaceutical segment rising by 32.58% and the medical services segment by 32.91% [4][21]. - Companies like BeiGene (百济神州) reported significant growth, achieving revenue of 27.595 billion yuan, a 44.2% increase year-on-year, surpassing the total revenue of 27.21 billion yuan for 2024 [4][22]. Business Development (BD) Trends - The business development landscape for innovative drug companies is evolving, with significant partnerships such as the 11.4 billion USD deal between Innovent Biologics and Takeda, and a 12.5 billion USD collaboration between Hengrui Medicine and GlaxoSmithKline [5][22][24]. - The total value of business development transactions reached approximately 94.158 billion USD in the first three quarters of 2025, significantly exceeding the total for 2024 [25]. CXO Sector Performance - The CXO sector, driven by the demand for innovative drug research, achieved a 32.91% increase in 2025, with total revenue of 1,365.72 billion yuan, up 3.63% year-on-year, and net profit of 209.12 billion yuan, up 36.47% year-on-year [10][27]. - Leading companies like WuXi AppTec (药明康德) and Kanglong Chemical (康龙化成) returned to growth, with WuXi AppTec reporting a revenue increase of 18.61% and net profit growth of 84.84% [28][31]. Traditional Chinese Medicine and Medical Devices - The traditional Chinese medicine sector experienced a modest increase of 6.75% in 2025, with total revenue of 2,590.69 billion yuan, down 4.33% year-on-year, and net profit of 294.99 billion yuan, down 1.53% year-on-year [36]. - The medical device sector reported a revenue of 1,792.10 billion yuan, down 2.24% year-on-year, with notable performance differences among sub-sectors, where companies like Mindray Medical (迈瑞医疗) showed strong overseas revenue growth [33][34].

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：贵公司对翰思艾泰-B的持有比例为多少？ 贝达药业（300558.SZ）12月31日在投资者互动平台表示，公司持有翰思艾泰生物医药科技（武汉）股 份有限公司5.45%的股份。 ...

贝达药业（300558.SZ）12月31日在投资者互动平台表示，您好！公司与康万达共同开发的抗体-溶瘤病 毒组合疗法（V113+BK-001）正在按计划推进中，如有重大节点公司会及时公告披露。谢谢！ （记者 曾健辉） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司与康万达合作开发的VM - 001项目，目前进 展如何？ ...